WYWeixian Yang

Weixian Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Weixian Yang has a total of 107 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lipoprotein(a) and Risk Stratification for Atherosclerotic Cardiovascular Disease Across the Cardiovascular‐Kidney‐Metabolic Continuum

    by Yanwen Fang, Xuyan Pei, Sizhuang Huang, Hao Zhang, Mingyang Li, Haihua Zhang, Weixian Yang, Mengyue Yu

    Background: Lp(a) (lipoprotein(a)) is an established risk factor for atherosclerotic cardiovascular disease (ASCVD), but its prognostic relevance across the cardiovascular‐kidney‐metabolic (CKM) continuum remains uncertain. We examined whether Lp(a) was associated with incident ASCVD across CKM stages and whether it provided complementary risk stratification beyond CKM staging. Methods: We included 333 321 UK Biobank participants free of clinical cardiovascular disease at baseline and classified them into CKM stages 0 to 3. Elevated Lp(a) was defined as ≥125 nmol/L. The primary outcome was incident ASCVD, defined as coronary artery disease or ischemic stroke. Cox proportional hazards models were used to estimate hazard ratios (HRs), and 10‐year absolute risks were estimated using Kaplan–Meier methods. Results: During a median follow‐up of 15.3 years, 17 581 incident ASCVD events occurred. After adjustment for demographic characteristics, socioeconomic factors, lifestyle factors, low‐density lipoprotein cholesterol, medications, and CKM stage, elevated Lp(a) was associated with higher ASCVD risk (HR, 1.31 [95% CI, 1.25–1.36]). In joint analyses, risk increased progressively across combined CKM–Lp(a) categories, with the highest risk observed in participants with CKM stage 3 and elevated Lp(a) versus CKM stage 0 and lower Lp(a) (HR, 3.43 [95% CI, 2.74–4.31]). Ten‐year ASCVD risk ranged from 0.64% to 16.30%, and the absolute risk difference associated with elevated Lp(a) increased from 0.23% in stage 0 to 2.20% in stage 3. Conclusions: Elevated Lp(a) was associated with higher incident ASCVD risk across the CKM continuum. Although relative associations were broadly consistent across CKM stages, absolute risk increments associated with elevated Lp(a) were greater at more advanced CKM stages, supporting the integration of Lp(a) into CKM‐based risk stratification for primary prevention.


  • Open Access

    Complementary Cardiohepatic Prognostic Value of Hepatic Steatosis in Cardiovascular-Kidney-Metabolic Syndrome

    by Ying Xiao, Sizhuang Huang, Hongzhao You, Dong Liu, Jiansong Yuan, Mengyue Yu, Weixian Yang

  • Open Access

    Single-Cell Transcriptomics Reveals the Immune Pathogenesis of Isolated Coronary Arteritis Presenting as Refractory In-Stent Restenosis

    by Miao Yu, Yu Jiang, Ji Huang, Zhi-Yao Wei, Zhi-Feng Song, Fang-Shun Tan, Si-Zhuang Huang, Jian-Song Yuan, Shao-Dong Ye, Jin-Gang Cui, et al.

  • Platelet membrane-fusing MSC-derived apoptotic extracellular vesicles enhanced cardiac repair after ischemia/reperfusion injury

    by Zhifeng Song, Fangshun Tan, Yu Jiang, Shuo Wang, ZhiYao Wei, Miao Yu, Hongrui Yu, YanXia Tu, Liaoming He, Weixian Yang, et al.

  • Open Access

    Mediating effect of insulin resistance in the relationship between dietary inflammatory index and cardiovascular–kidney–metabolic syndrome stage in US adults, 2007–2018

    by Ying Xiao, Hongzhao You, Tianjie Wang, Yan Zeng, Yingxuan Zhu, Rui Zhang, Dong Liu, Yanyan Zhao, Yilu Liu, Shijie You, et al.

    Background: Cardiovascular–kidney–metabolic (CKM) syndrome is a progressive, five-stage disease framework driven by interrelated cardiovascular, renal, and metabolic dysfunction, with chronic inflammation and insulin resistance (IR) playing key roles. The dietary inflammatory index (DII) quantifies overall dietary inflammatory potential, but its role in CKM staging remains unclear. Objective: This study aimed to evaluate the association between DII and CKM syndrome stage and to assess the potential mediating effect of IR. Design: This cross-sectional study used data from the National Health and Nutrition Examination Survey (2007–2018). DII was derived from 24-h dietary recall. CKM stages were defined by the American Heart Association criteria. IR was assessed using the triglyceride–glucose index (TyG), Metabolic Score for IR (METS-IR), and Homeostatic Model Assessment for IR (HOMA-IR). Statistical analyses were performed after accounting for the complex survey design. Results: Of the 27,635 participants, 94.08% had CKM syndrome (Stage 1 or higher). Compared with Stage 0, stepwise increases in the adjusted odds ratios for a higher DII score were observed across CKM stages (Q4 vs. Q1: 1.67 [1.31–2.15] for Stage 1; 2.11 [1.63–2.73] for Stage 2; 2.32 [1.08–4.98] for Stage 3; and 4.19 [2.65–6.63] for Stage 4). Restricted cubic splines models confirmed the positive linear association between DII and each CKM stage (all Poverall < 0.05; Pnon-linear > 0.05), with increasingly steep slopes at higher stages. TyG, METS-IR, and HOMA-IR mediated 30.7, 45.0, and 25.3% of the association between DII and CKM syndrome stage, respectively. Conclusions: Pro-inflammatory diet, as indicated by a higher DII score, was positively associated with more advanced CKM syndrome stage, partly mediated by IR. The DII may serve as a practical measure of dietary inflammation in CKM management.


  • Open Access

    Glucocorticoid Therapy for Recurrent In-Stent Restenosis

    by Miao Yu, Hang-Yu Yan, Zhi-Yao Wei, Yu Jiang, Zhi-Feng Song, Hong-Zhao You, Wei-Xian Yang, Hai-Yan Qian


  • Open Access

    Cardiogenic shock revisited: From hemodynamic-centric to multimodal precision care

    by Xuanqi An, Chengliang Yin, Haobo Xu, Zeye Liu, Qing Gu, Jing-Chao Luo, Yahui Lin, Chao Guo, Xiaofei Li, Hanyang Liang, et al.

  • Open Access

    Association of serum total bilirubin with recurrent cardiovascular events in patients with in-stent restenosis: a stratified analysis by inflammatory status

    by Miao Yu, Yu Jiang, Yu Sun, Han Zhang, Tian-Jie Wang, Tao Tian, Jian-Song Yuan, Hai-Yan Qian, Wei-Xian Yang

    In-stent restenosis (ISR) remains a major clinical challenge despite advances in stent technology and pharmacotherapy. While inflammation plays a pivotal role in ISR progression, the prognostic value of stable biomarkers reflecting chronic inflammation has not been fully explored. This study examined the association of serum total bilirubin (TBIL), alone and in combination with high-sensitivity C-reactive protein (hsCRP), with long-term cardiovascular outcomes in ISR patients undergoing percutaneous coronary intervention (PCI). A total of 2055 ISR patients who underwent repeat PCI at Fuwai Hospital from January 2017 to December 2018 were consecutively enrolled. Patients were stratified based on TBIL and hsCRP levels. The primary endpoint was the incidence of major adverse cardiovascular events (MACEs), including all-cause mortality, myocardial infarction, stroke, repeat revascularization and stent thrombosis. Multivariable Cox regression and subgroup analyses were conducted. During a median follow-up of 36 months, 457 patients suffered from MACEs. Lower TBIL levels were independently associated with a higher risk of long-term MACEs, regardless of high hsCRP (hsCRP ≥ 2 mg/L, hazard ratio [HR] = 1.865, 95% confidence interval [CI] 1.423–2.443, P < 0.001) or low hsCRP (hsCRP < 2 mg/L HR = 1.338, 95% CI: 1.039–1.721, P = 0.024). Kaplan-Meier curves showed that patients with both low TBIL and elevated hsCRP had the highest incidence of MACEs (P < 0.001). The combination of TBIL and hsCRP provided additional risk stratification information, especially in patients with diabetes mellitus (P for interaction = 0.001). Serum TBIL is a novel, independent predictor of adverse outcomes in ISR patients and provides complementary value to hsCRP for risk stratification. Its clinical utility may be particularly valuable in diabetic populations, suggesting that TBIL may help identify higher-risk subgroups within ISR populations. This study is not a registered clinical trial. Clinical trial registration: not applicable. The online version contains supplementary material available at 10.1186/s12872-026-05680-5.


  • Open Access

    Early Detection of Atrial Fibrillation in Psoriasis Patients: A Machine Learning Model Integrating Clinical, Proteomic, Metabolomic and Genetic Data

    by Fangshun Tan, Mengyuan Wang, Ruizhi Wang, Cuntai Zhang, Jiansong Yuan, Jing Xu, Weixian Yang

    Background: Owing to chronic inflammation, atrial fibrillation (AF) is more likely to occur in patients with psoriasis. Thus, early AF detection in psoriasis patients is essential for timely prevention and intervention for further complications.Objectives: We aim to develop and validate a multi-modal machine learning (ML) model integrating clinical, proteomic, metabolomic and Polygenic Risk Score (PRS) data to accurately predict AF risks in patients with psoriasis.Methods: Collecting data from 10,696 psoriasis patients in the UK Biobank, five predictive models were constructed using 14 ML algorithms (70% training, 30% validation) with 20-fold cross-validation: clinical model, clinical-proteomic model, clinical-metabolomic model, clinical-PRS model and fully integrated clinical-proteomic-metabolomic-PRS model. Feature selection was performed using LASSO, Boruta, Random Forest (RF) and XGBoost. Model performance was assessed using the area under the receiver operating characteristic curve (AUC), net reclassification improvement (NRI), integrated discrimination improvement (IDI), decision curve analysis (DCA), and SHapley Additive exPlanations (SHAP). Unsupervised clustering identified distinct psoriasis phenotypes associated with AF risk.Results: Nine significant independent features were identified in our model, including four clinical features (i.e., age, basal metabolic rate (BMR), weight and Cystatin C), one metabolomic features (i.e., HDL-free cholesterol percentage), three proteomic features (i.e., NT-proBNP, GPA33, TCL1A) and PRS. The full multi-modal model (CATBoost) achieved superior predictive performance with an AUC of 0.858 (95% confidence interval: 0.786–0.930). It significantly outperformed the clinical-only model (AUC=0.750) and established clinical risk scores (e.g., CHARGE-AF AUC=0.772, C2HEST AUC=0.623). Clustering analysis based on six core biomarkers revealed two distinct patient subtypes with markedly divergent AF risk profiles.Conclusion: A multifactorial model integrating clinical, metabolic, proteomic and genetic features for predicting AF risks in patients with psoriasis was constructed to better serve clinical settings.

  • Open Access

    Ability of the DHAM Score to Predict 5‐Year All‐Cause Mortality in Patients With Diabetes and Comorbid Hypertension: Validation and Risk Stratification in Two Prospective Cohorts

    by Yilu Liu, Yingxuan Zhu, Jiansong Yuan, Lili Liu, Dingyue Zhang, Rui Zhang, Shijie You, Yingdong Han, Hongzhao You, Shouling Wu, et al.

    Objective: Individuals with both diabetes and hypertension face a heightened risk of all‐cause death. We aimed to validate the DHAM score′s performance in predicting 5‐year overall mortality in two prospective cohorts. Methods: The internal validation cohort comprised 3291 patients with diabetes and hypertension drawn from the 1999–2014 cycles of the National Health and Nutrition Examination Survey database. The external validation cohort comprised 2478 patients from the 2008–2015 China Kailuan cohort. The DHAM score was constructed from eight predictors (age, sex, education, marriage, smoking, cardiovascular disease, serum albumin, and urea nitrogen). Renal dysfunction was determined by an estimated glomerular filtration rate < 60 mL/min/1.73 m 2 computed via the Chronic Kidney Disease Epidemiology Collaboration equation. Results: The C‐index was 0.758 (95% CI: 0.743–0.833) in the NHANES database and 0.741 (95% CI: 0.731–0.790) in the Kailuan cohort. A DHAM score > 148 independently predicted 5‐year all‐cause death in NHANES (adjusted‐HR 10.03, 95% CI: 3.37–18.83, p < 0.001); after recalibration, a score > 152 independently predicted mortality in Kailuan (adjusted‐HR 9.24, 95% CI: 4.71–16.84, p < 0.001). The patients were further stratified by DHAM score and renal function into three risk groups. Intermediate‐ and high‐risk categories showed higher 5‐year all‐cause death rates than low‐risk categories across both cohorts (log‐rank p < 0.001). Conclusion: The DHAM score had a robust prognostic value for 5‐year all‐cause death among individuals with both diabetes and hypertension. Higher DHAM score combined with renal dysfunction could identify patients at highest risk of all‐cause death. Trial Registration: Chinese Registry of Clinical Trials: ChiCTR2000029767